

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER FOR PATENTS PO Box 1450 Alexandria, Virginia 22313-1450 www.emplo.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/567,022	07/14/2006	Yasuhiro Nakano	P29235	9439
7055 7590 60/15/2009 GREENBLUM & BERNSTEIN, P.L.C. 1950 ROLAND CLARKE PLACE			EXAMINER	
			CHRISTIAN, MARJORIE ELLEN	ARJORIE ELLEN
RESTON, VA	20191		ART UNIT	PAPER NUMBER
			1797	
			NOTIFICATION DATE	DELIVERY MODE
			06/15/2009	ELECTRONIC

# Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

gbpatent@gbpatent.com pto@gbpatent.com

## Application No. Applicant(s) 10/567.022 NAKANO ET AL. Office Action Summary Examiner Art Unit MARJORIE CHRISTIAN 1797 -- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --Period for Reply A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS. WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status 1) Responsive to communication(s) filed on 21 March 2007. 2a) This action is FINAL. 2b) This action is non-final. 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213. Disposition of Claims 4) Claim(s) 1-16 is/are pending in the application. 4a) Of the above claim(s) is/are withdrawn from consideration. 5) Claim(s) \_\_\_\_\_ is/are allowed. 6) Claim(s) \_\_\_\_\_ is/are rejected 7) Claim(s) is/are objected to. 8) Claim(s) 1-16 are subject to restriction and/or election requirement. Application Papers 9) The specification is objected to by the Examiner. 10) The drawing(s) filed on is/are; a) accepted or b) objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abevance. See 37 CFR 1.85(a). Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152. Priority under 35 U.S.C. § 119 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some \* c) None of: Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). \* See the attached detailed Office action for a list of the certified copies not received.

1) Notice of References Cited (PTO-892)

Notice of Draftsperson's Patent Drawing Review (PTO-948)

Attachment(s)

Interview Summary (PTO-413)
Paper No(s)/Mail Date. \_\_\_\_\_.

6) Other:

5) Notice of Informal Patent Application

Page 2

Application/Control Number: 10/567,022

Art Unit: 1797

### DETAILED ACTION

### Election/Restrictions

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, <u>claims 1-6, 10-13, 15-16</u>, drawn to a composite porous membrane comprising an organic porous membrane and porous support.

Group II, claims 7-8, drawn to a process of making a composite porous membrane.

Group III, claims 9, 14, drawn to a processes of using the composite porous membrane.

The inventions listed as Groups I-III do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same of corresponding special technical features for the following reasons:

The inventions listed as Groups I-III do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features. Specifically, US PGPub 2003/0150808, MORIKAWA et al. (hereinafter MORIKAWA) discloses a similar special technical feature. The special feature disclosed as a composite porous membrane (Abstract) comprising a porous support and organic polymer porous membrane that penetrates the porous support (Abstract, Ex. 1-2, Comp. Ex. 1-4, Figs. 1-6), wherein the porous membrane has an average pore diameter of 0.1 to 50 µm and standard deviation of 0 to 0.6 (specifically Ex. 2, Comp. Ex. 3-4); membrane thickness to pore diameter ratio of

Application/Control Number: 10/567,022

Art Unit: 1797

0.05 to 2 (referring to macrovoid and microcracks diameters) (specifically Ex. 1-2, Comp. Ex. 3-4 and the scaled Fig. 4, where it appears the thickness of B is approximately 60 µm and the specification discloses average macrovoid diameters of about 30 µm in the porous membrane and support); opening ratio between 10 and 90% (specifically the microcracks in Comp. Ex. 1 and Figs. 3-4), percentage of through pores greater than 30% (Figs. 3-4, Comp. Ex. 1), and structure in which adjacent pores communicate with one another (Figs. 3-4); and where the supporting porous membrane

also has macrovoids on the composite membrane (continuous pores) with a diameter of 0.14\*A-0.05\*A (Ex. 1-2, Comp. Ex. 1) (more than 0.5 µm) and the thickness of A is 220 µm (referring also to Claim 7), where macrovoids are implicitly present in the multi-layer composite membrane of Ex. 2. since it uses the same method of production as Ex. 1.

This application contains claims directed to more than one species of the generic invention. These species are deemed to lack unity of invention because they are not so linked as to form a single general inventive concept under PCT Rule 13.1.

The species are as follows:

Claim 9, drawn to a process of producing a hemocyte suspension.

Claim 14, drawn to a process of culturing cells.

Applicant is required, in reply to this action, to elect a single species to which the claims shall be restricted if no generic claim is finally held to be allowable. The reply must also identify the claims readable on the elected species, including any claims

Application/Control Number: 10/567,022

Art Unit: 1797

subsequently added. An argument that a claim is allowable or that all claims are generic is considered non-responsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

There is no generic claim.

The species listed above do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, the species lack the same or corresponding special technical features. As shown above the processes do not relate to a single inventive concept as the special feature is disclosed by MORIKAWA. Further the process of <u>Claim 9</u> requires multiple filters and a hemocyte suspension to remove leuckocytes, the process of <u>Claim 14</u> requires a cell culture solution and co-culturing cells on regions; these are entirely different processes with different technical features that require separate searches and consideration.

 A telephone call was made to Mr. Stephen M. Roylance on 6/10/2009 to request an oral election to the above restriction requirement, but did not result in an election being made.

Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement may be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To preserve a right to petition, the election must be made with traverse. If the reply does Art Unit: 1797

not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

#### Conclusion

4. Any inquiry concerning this communication or earlier communications from the examiner should be directed to MARJORIE CHRISTIAN whose telephone number is (571)270-5544. The examiner can normally be reached on Monday through Thursday 7-5pm (Fridays off).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Vickie Kim can be reached on (571)272-0579. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Krishnan S Menon/ Primary Examiner, Art Unit 1797